Thanks for your feedback Sean. I wanted to use the timeline approach to make an analysis.

I'm hoping for some feedback regarding whether anyone thinks the combination of VIR-1388 with long acting ll would be good in that one blocks the entry of hiv to the cd-4 t lymphocyte while the other locates and destroys hiv.

also, if long acting ll is only 2 amino acid change from regular ll, then, will it require a phase I clinical trial or can it go straight to phase II?